AbbVie Unveils New Data on Venetoclax for Untreated CLL at EHA 2026

In a significant revelation, AbbVie (NYSE: ABBV) has presented compelling new data on Venetoclax, an innovative treatment for untreated chronic lymphocytic leukemia (CLL), during the European Hematology Association (EHA) 2026 conference held in Stockholm, Sweden from June 11-14, 2026. The pivotal results from the phase III CLL14 trial, which studied the efficacy of fixed-duration combination therapy involving Venetoclax, were formally disclosed, emphasizing the long-term benefits seen over a remarkable nine-year period.

According to Daejin Abidoye, Vice President and Head of Oncology at AbbVie, the nine-year results from the landmark CLL14 trial substantiate the sustained safety and efficacy of Venetoclax. He stated, "These results support the use of Venetoclax-based combination therapies as first-line treatments for a wide array of CLL patients, building substantial evidence in these clinical settings. After one year of fixed-duration therapy, patients experience an unprecedented duration before the initiation of subsequent treatments, thereby enhancing their treatment-free intervals. This study moves us closer to our mission of transforming care for patients living with difficult-to-treat blood cancers, allowing for improved outcomes."

Kirsten Fischer, MD, an investigator of the CLL14 trial at University Hospital Cologne, affirmed that Venetoclax in combination with Obinutuzumab demonstrated notable benefits when compared to Chlorambucil and Obinutuzumab. "The combination therapy notably extended progression-free survival (PFS) significantly, with a median time to next treatment of approximately eight years, highlighting the sustainable efficacy of this therapeutic approach for CLL patients,” Fischer commented, indicating the potential for prolonged periods without the need for treatment.

The phase III CLL14 trial, meticulously coordinated with the German CLL Study Group, enrolled untreated CLL patients, particularly those with comorbidities. The aim was to compare the efficacy and safety of the Venetoclax and Obinutuzumab regimen against the Chlorambucil and Obinutuzumab pairing. The final analysis unveiled that patients receiving the Venetoclax combination not only had extended PFS but also served as a novel limited-duration treatment option for patients inadequately fit for standard therapy. Long-term analysis spanning nine years verified the efficacy and safety of the fixed-duration combination therapy, with the median time to next treatment noted at 7.6 years for the Venetoclax group.

Over a median follow-up period of 9.2 years, the PFS for the Venetoclax and Obinutuzumab cohort was significantly better compared to that of the Chlorambucil group, with median PFS rates reported at 6.4 years and 3.2 years respectively (hazard ratio [HR]: 0.50, 95% confidence interval [CI]: 0.39–0.63, p<0.001). While treatment-related adverse events were present, those occurring in the Venetoclax group included neutropenia, thrombocytopenia, infusion reactions, anemia, febrile neutropenia, pneumonia, and leukopenia, but generally remained manageable.

Chronic lymphocytic leukemia is one of the most common leukemias in adults, originating from precursor cells in the bone marrow that mature into lymphocytes. Patients often experience recurrent disease states after responding to prior treatments or can fall into treatment-resistant scenarios. Despite recent improvements in treatment outcomes, many patients still face challenges with prolonged treatment durations and ongoing disease management.

Overview of the CLL14 Phase III Trial

The multicenter, open-label, randomized phase III CLL14 trial (NCT02242942) was conducted with the cooperation of Germany's CLL Study Group (GCLLSG) and specifically targeted untreated CLL patients, assessing the efficacy and safety of the Venetoclax and Obinutuzumab regimen against the Chlorambucil and Obinutuzumab combination. Patient inclusion was limited to those exhibiting comorbidities defined by a Cumulative Illness Rating Scale (CIRS) score exceeding six or a creatinine clearance below 70 mL/min, ensuring a thorough evaluation of the treatment's impacts.

About Venetoclax

Venetoclax, a first-in-class medication, selectively binds and inhibits the BCL-2 protein, which is critical in preventing apoptosis – the programmed death of cancer cells. By targeting BCL-2, Venetoclax helps restore apoptotic processes, making it a vital part of CLL treatment strategies. It is co-developed by AbbVie and Roche, with approvals completed in over 80 countries, highlighting its international impact on CLL management.

AbbVie's Commitment to Oncology

AbbVie's commitment to enhancing treatment standards for patients facing difficulties with cancer is unwavering. With a robust pipeline focusing on various malignancies, AbbVie strives to innovate targeted therapies that can essentially suppress or eliminate cancer cell growth. Through collaborations with expert teams and pioneering partners, AbbVie endeavors to elevate patient access to proficient cancer treatments.